Virco establishes comprehensive set of clinical cutoffs for the virco®TYPE HIV-1 resistance test

October 31, 2004

Washington, D.C., October 31, 2004 - Investigators from Virco today presented data that establishes a comprehensive set of clinical cutoffs -- a newly established threshold for optimal selection and evaluation of antiretroviral regimens -- for the virco®TYPE HIV-1 resistance test. These reference values are derived from the largest clinical outcomes database used to generate clinical cutoffs, and apply a consistent and clinically relevant approach to help physicians better evaluate HIV drug resistance information. These clinical cutoffs are available for a wider range of antiretroviral drugs than those offered by other HIV resistance tests.

In her presentation today at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Lee Bacheler, PhD, vice president, Clinical Virology, at Virco, demonstrated how clinical cutoffs for the virco®TYPE HIV-1 assay, based on a large and high-quality outcomes database that incorporates more than 3,000 therapeutic regimens, provide physicians with clinically relevant resistance information. She and her colleagues employed virco®TYPE analysis of viral genotypes to predict quantitative phenotypic resistance levels. Mathematical models of virologic response to antiretroviral drugs at eight and 24 weeks versus baseline fold change in IC50 (concentrations of drugs that inhibit 50% of viral replication) were constructed using linear regression. Clinical cutoffs (CCOs) were defined as virco®TYPE-predicted fold change values for 20% and 80% loss of viral load response.

"Our study supports the value of clinical cutoffs in facilitating rational selection of antiretroviral treatment," commented Dr. Bacheler. "The clinical cutoffs enhance the value of the virco®TYPE HIV-1 test by applying consistent definitions across antiretroviral drugs. The results are more closely related to actual treatment practices, with the potential to improve medical management of people with HIV."

Dr. Bacheler reported that baseline fold change (FC) values associated with a modest reduction (20%) in the eight-week viral load response were low, whereas baseline fold change values associated with a more substantial (80%) loss of viral load response were often quite high. However, in both cases, these FC values were higher than those derived from wild-type clinical isolates

Clinical cutoff ranges: clinical response at eight weeks1 FC values of wild type clinical isolates 0.6 to 0.9

CCOs based on 24-week outcome data were similar, Dr. Bacheler observed.1 A summary of her ICAAC presentation, including the CCO values, will be available for download at

"The predictive value of the virco®TYPE analysis, through the use of clinical cutoffs, has profound implications for the practicing physician," commented Calvin J. Cohen, MD, MSc, of the Community Research Initiative of New England. "These data are critical to helping physicians optimize treatment regimens, as they provide valuable insight into how to interpret a resistance test."

Advantages of the virco®TYPE HIV-1 Test

The virco®TYPE HIV-1 test is the first resistance test that provides phenotypic information and expert clinical knowledge at a fraction of the cost of conventional phenotyping, and the only resistance test to which consistent CCOs can be applied. Compared to biological cutoffs, CCOs represent a different, more clinically relevant approach to interpreting resistance information, providing a higher degree of correlation with virologic outcomes. Additionally, unlike the approach for biologic cutoffs, the approach used to determine CCOs considers the effects of drugs used in combination regimens.

The virco®TYPE HIV-1 report reflects genotypic and phenotypic analysis, informed by Virco's proprietary Expert Clinical Knowledge. The test yields rapid, cost-effective results within 48 hours.
About Virco BVBA

Virco BVBA is a world leader in the field of HIV resistance testing services for clinical practice and clinical studies, advancing research that correlates laboratory testing with clinical management, while offering a wide range of HIV resistance diagnostics. The company applies the latest technologies in molecular biology, medical virology and bio-informatics to develop advanced diagnostic tools that are based on pharmacogenomic principles of individualized patient care. A pioneer in HIV resistance testing, Virco has one of the world's largest repositories of HIV clinical isolates, a database of more than 65,000 phenotypes and more than 190,000 genotypes, and cutting-edge bio-informatics capabilities. These assets enable access to phenotypic information, via the virco®TYPE HIV-1 report, at an affordable cost and in a timely fashion.

Sensei Health

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to